|
1）小池和彦，小西和記，長岐為一郎．GSK548470（テノホビル ジソプロキシルフマル酸塩: TDF）の核酸アナログ製剤未治療の代償性B型慢性肝疾患（CHB）に対する第Ⅲ相臨床試験（48週中間集計）．肝臓．2014; 55: A42
|
|
|
|
2）鈴木義之，小西弘記，長岐為一郎，他．GSK548470（テノホビル ジソプロキシルフマル酸塩: TDF）の他剤効果不良の代償性B型慢性肝疾患（CHB）に対する第Ⅲ相臨床試験（48週中間集計）．肝臓．2014; 55: A242
|
|
|
|
|
|
3）Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014; 59: 434-42
|
|
|
|
|
4）林 紀夫，清澤研道，坪内博仁，他．B型慢性肝炎患者に対するペグインターフェロンα-2aの有効性及び安全性の検討．肝臓．2012; 53: 135-46
|
|
|
|
|
|
5）Piccolo P, Lenci I, di Paolo D, et al. A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther. 2013; 18: 57-64
|
|
|
|
|
|
6）Enomoto M, Nishiguchi S, Tamori A, et al. Entecavir and interferon-alpha sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol. 2013; 48: 397-404
|
|
|
|
|
|
7）Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011; 140: 132-43
|
|
|
|
|
|
8）Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011; 53: 62-72
|
|
|
|
|
|
9）Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013; 381: 468-75
|
|
|
|
|
|
10）van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006; 44: 318-25
|
|
|
|
|
|
11）Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008; 48: 391-8
|
|
|
|
|
|
12）van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010; 51: 73-80
|
|
|
|
|
|
13）Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011; 60: 247-54
|
|
|
|
|
|
14）Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 2012; 56: 520-6
|
|
|
|
|
|
15）Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014; 146: 980-8
|
|
|
|
|
|
16）Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008; 48: 750-8
|
|
|
|
|
|
17）Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131: 1743-51
|
|
|
|
|
|
18）Tamori A, Enomoto M, Kobayashi S, et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat. 2010; 17: 123-9
|
|
|
|
|
|
19）Jung YK, Yeon JE, Choi JH, et al. Fanconiʼs Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient. Gut Liver. 2010; 4: 389-93
|
|
|
|
|
|
20）Law ST, Li KK, Ho YY. Nephrotoxicity, including acquired Fanconiʼs syndrome, caused by adefovir dipivoxil - is there a safe dose? J Clin Pharm Ther. 2012; 37: 128-31
|
|
|
|
|
|
21）Fung J, Seto WK, Lai CL, et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014; 29: 428-34
|
|
|
|
|
|
22）Rodriguez-Novoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf. 2010; 9: 545-59
|
|
|
|
|
|
23）Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359: 2442-55
|
|
|
|
|
|
24）Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003; 10: 298-305
|
|
|
|
|